Boswellia (AKBA) vs Cartalax
A side-by-side research comparison of Boswellia (AKBA) and Cartalax across mechanism, dosing, half-life, benefits, side effects and research status.
Comparison table
| Attribute | Boswellia (AKBA) | Cartalax |
|---|---|---|
| Full name | Boswellia Serrata Extract (AKBA) | Cartalax (Ala-Glu-Asp-Gly Cartilage Bioregulator) |
| Category | Pain & Inflammation | Pain & Inflammation |
| Status | OTC supplement | Research compound (peptide bioregulator) |
| Mechanism | AKBA (acetyl-11-keto-beta-boswellic acid) selectively inhibits 5-lipoxygenase (5-LOX), reducing pro-inflammatory leukotrienes. This targets a different inflammatory pathway than NSAIDs (which act on COX), sparing the stomach lining. | As a signal peptide (Ala-Glu-Asp-Gly), it is proposed to regulate gene expression in chondrocytes and connective tissue, supporting cartilage matrix maintenance and anti-inflammatory tissue signaling. |
| Molecular weight | 512.7 Da (AKBA) | ~390 Da |
| Half-life | ~6 hours (AKBA) | Short (peptide) |
| Bioavailability | Low; improved by AKBA-standardized and phytosome forms | Oral (encapsulated) or subcutaneous |
| Typical dose | 100-250 mg AKBA-standardized, 1-2x daily | ~1-2 capsules/day or short injectable courses |
| Frequency | 1-2x daily | Once daily |
| Route | Oral capsule | Oral capsule or subcutaneous |
Boswellia (AKBA) reported benefits
- Reduces joint pain and stiffness
- Non-NSAID (stomach-sparing) anti-inflammatory
- Supports gut inflammation (IBD research)
- Cartilage protection
- Anti-inflammatory via 5-LOX inhibition
Cartalax reported benefits
- Cartilage/joint tissue support
- Connective tissue maintenance (proposed)
- Anti-inflammatory tissue signaling
- Short course-based protocol
Related comparisons
Research and educational reference only. Not medical advice.